Bioton S.A.
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes m… Read more
Bioton S.A. (BIO) - Net Assets
Latest net assets as of June 2025: zł588.01 Million PLN
Based on the latest financial reports, Bioton S.A. (BIO) has net assets worth zł588.01 Million PLN as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł763.75 Million) and total liabilities (zł175.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł588.01 Million |
| % of Total Assets | 76.99% |
| Annual Growth Rate | 4.51% |
| 5-Year Change | -4.7% |
| 10-Year Change | -26.79% |
| Growth Volatility | 50.88 |
Bioton S.A. - Net Assets Trend (2005–2024)
This chart illustrates how Bioton S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bioton S.A. (2005–2024)
The table below shows the annual net assets of Bioton S.A. from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł590.55 Million | -2.61% |
| 2023-12-31 | zł606.36 Million | +0.05% |
| 2022-12-31 | zł606.06 Million | -2.68% |
| 2021-12-31 | zł622.74 Million | +0.50% |
| 2020-12-31 | zł619.64 Million | +6.47% |
| 2019-12-31 | zł582.00 Million | -18.35% |
| 2018-12-31 | zł712.79 Million | -7.82% |
| 2017-12-31 | zł773.25 Million | -4.99% |
| 2016-12-31 | zł813.83 Million | +0.89% |
| 2015-12-31 | zł806.64 Million | -44.20% |
| 2014-12-31 | zł1.45 Billion | +4.37% |
| 2013-12-31 | zł1.39 Billion | +3.63% |
| 2012-12-31 | zł1.34 Billion | -3.48% |
| 2011-12-31 | zł1.38 Billion | +18.38% |
| 2010-12-31 | zł1.17 Billion | +8.33% |
| 2009-12-31 | zł1.08 Billion | -12.74% |
| 2008-12-31 | zł1.24 Billion | +39.57% |
| 2007-12-31 | zł886.79 Million | +9.74% |
| 2006-12-31 | zł808.11 Million | +216.39% |
| 2005-12-31 | zł255.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bioton S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3122.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł1.72 Billion | 290.79% |
| Other Comprehensive Income | zł-86.68 Million | -14.68% |
| Other Components | zł57.13 Million | 9.67% |
| Total Equity | zł590.55 Million | 100.00% |
Bioton S.A. Competitors by Market Cap
The table below lists competitors of Bioton S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mifflinburg Bancorp Inc
PINK:MIFF
|
$42.41 Million |
|
Fortune Information Systems Corp
TW:2468
|
$42.41 Million |
|
Australian Strategic Materials Ltd
PINK:ASMMF
|
$42.43 Million |
|
0FUW
LSE:0FUW
|
$42.43 Million |
|
Arctic Paper SA
WAR:ATC
|
$42.39 Million |
|
Nabaltec AG
F:NTG
|
$42.39 Million |
|
MICROPOLE S.A.INH. EO-05
F:MP4
|
$42.38 Million |
|
BIT Computer Co. Ltd
KQ:032850
|
$42.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioton S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 606,358,000 to 590,548,000, a change of -15,810,000 (-2.6%).
- Net loss of 15,658,000 reduced equity.
- Other comprehensive income decreased equity by 153,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-15.66 Million | -2.65% |
| Other Comprehensive Income | zł-153.00K | -0.03% |
| Other Changes | zł1.00K | +0.0% |
| Total Change | zł- | -2.61% |
Book Value vs Market Value Analysis
This analysis compares Bioton S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.59x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.40x to 0.59x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | zł10.33 | zł4.09 | x |
| 2006-12-31 | zł31.96 | zł4.09 | x |
| 2007-12-31 | zł32.34 | zł4.09 | x |
| 2008-12-31 | zł36.36 | zł4.09 | x |
| 2009-12-31 | zł23.41 | zł4.09 | x |
| 2010-12-31 | zł20.57 | zł4.09 | x |
| 2011-12-31 | zł21.30 | zł4.09 | x |
| 2012-12-31 | zł17.41 | zł4.09 | x |
| 2013-12-31 | zł15.37 | zł4.09 | x |
| 2014-12-31 | zł15.85 | zł4.09 | x |
| 2015-12-31 | zł9.59 | zł4.09 | x |
| 2016-12-31 | zł9.68 | zł4.09 | x |
| 2017-12-31 | zł9.19 | zł4.09 | x |
| 2018-12-31 | zł8.30 | zł4.09 | x |
| 2019-12-31 | zł6.78 | zł4.09 | x |
| 2020-12-31 | zł7.22 | zł4.09 | x |
| 2021-12-31 | zł7.04 | zł4.09 | x |
| 2022-12-31 | zł7.06 | zł4.09 | x |
| 2023-12-31 | zł7.06 | zł4.09 | x |
| 2024-12-31 | zł6.88 | zł4.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioton S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.54%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.34x
- Recent ROE (-2.65%) is above the historical average (-6.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 13.56% | 22.84% | 0.42x | 1.40x | zł9.09 Million |
| 2006 | 11.73% | 43.02% | 0.22x | 1.26x | zł13.69 Million |
| 2007 | 3.05% | 9.81% | 0.18x | 1.77x | zł-60.66 Million |
| 2008 | -20.16% | -75.99% | 0.14x | 1.87x | zł-333.69 Million |
| 2009 | -59.75% | -209.58% | 0.18x | 1.60x | zł-700.28 Million |
| 2010 | 10.12% | 29.25% | 0.24x | 1.45x | zł1.36 Million |
| 2011 | -7.01% | -29.05% | 0.14x | 1.69x | zł-203.64 Million |
| 2012 | 3.04% | 9.31% | 0.21x | 1.54x | zł-86.56 Million |
| 2013 | -0.50% | -1.89% | 0.18x | 1.46x | zł-136.35 Million |
| 2014 | 0.27% | 0.97% | 0.19x | 1.44x | zł-132.39 Million |
| 2015 | -63.51% | -129.29% | 0.32x | 1.52x | zł-605.18 Million |
| 2016 | -3.44% | -10.29% | 0.21x | 1.56x | zł-111.66 Million |
| 2017 | -0.92% | -2.01% | 0.32x | 1.45x | zł-86.15 Million |
| 2018 | 3.68% | 10.89% | 0.24x | 1.42x | zł-45.01 Million |
| 2019 | -21.77% | -62.71% | 0.23x | 1.51x | zł-184.89 Million |
| 2020 | 5.47% | 15.29% | 0.26x | 1.40x | zł-28.04 Million |
| 2021 | 0.48% | 1.77% | 0.19x | 1.43x | zł-57.57 Million |
| 2022 | 0.23% | 0.61% | 0.29x | 1.34x | zł-59.19 Million |
| 2023 | 0.38% | 1.25% | 0.22x | 1.36x | zł-58.36 Million |
| 2024 | -2.65% | -7.54% | 0.26x | 1.34x | zł-74.71 Million |
Industry Comparison
This section compares Bioton S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $26,365,545
- Average return on equity (ROE) among peers: -54.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioton S.A. (BIO) | zł588.01 Million | 13.56% | 0.30x | $42.39 Million |
| Bioceltix S.A. (BCX) | $1.91 Million | -83.78% | 0.69x | $71.31 Million |
| Captor Therapeutics S.A. (CTX) | $124.20 Million | -26.23% | 0.16x | $69.93 Million |
| Mabion S.A. (MAB) | $-54.16 Million | 0.00% | 0.00x | $31.56 Million |
| Molecure S.A. (MOC) | $126.45 Million | -10.71% | 0.09x | $21.11 Million |
| Nanogroup SA (NNG) | $8.37 Million | -119.60% | 1.43x | $12.30 Million |
| Pharmena S.A. (PHR) | $8.98 Million | -45.66% | 0.29x | $2.62 Million |
| PolTREG S.A. (PTG) | $12.83 Million | -6.84% | 0.27x | $16.72 Million |
| Pure Biologics Spólka Akcyjna (PUR) | $7.21 Million | -65.22% | 2.02x | $2.90 Million |
| Ryvu Therapeutics SA (RVU) | $1.50 Million | -131.36% | 5.84x | $100.54 Million |